The global market for the Connected Drug Delivery Devices is anticipated to develop at a compound annual growth rate (CAGR) of 16.69% throughout the course of the forecast, to reach USD 928.38 million by 2028.
The growing occurrences of chronic diseases is likely to influence the growth of connected drug delivery devices market size. The continuous product innovation, many products in pipeline and mergers and collaboration activities are some factors that help in growth of connected drug delivery devices market share across the map. At the same time, issues due to excessive usage of nasal sprays may restraint the growth of connected injectable drug delivery devices market. Furthermore, there is a threat of local side effects and reduced bioavailability are also factors hampering the market growth.
Nasal drug delivery technology is the supervision of a drug via the nasal path. The growing preference by patients for nasal drug as an option for better efficiency and easy to administrate. The increased preference of self-use practice is one of the major reasons influencing the growth of nasal drug delivery technology market. Furthermore, there has been a substantial increase in sale of over-the-counter nasal spray drugs and the increased focus on substitute ways of drug delivery are reasons effecting the market growth.
The global connected drug delivery devices market is segmented into several classifications including product outlook, end-user outlook, technology outlook, and regional outlook. Based on the product outlook the connected drug delivery devices market is categorized by connected sensors, inhaler sensors, injection sensors, integrated connected devices, integrated inhalation devices, integrated injection devices. Furthermore, on the basis of end-users outlook the market is fragmented into healthcare providers, and homecare centers. Based on the technology outlook the global connected drug delivery devices is divided into Bluetooth, NFC, other technologies such as cellular, low power wide area network. Discussing the regional outlook, the connected drug delivery devices market is widely range to North America, U.S., Canada, Europe, U.K., Germany, Asia Pacific, Japan, China, Latin America, Brazil, Mexico, and Middle East & Africa, South Africa.
Leading players of the global connected drug delivery devices market include Proteus Digital Health, Adherium Ltd., Merck KGaA, Propeller Health, and BIOCORP.
Connected Drug Delivery Devices Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 928.38 million|
|Growth Rate||CAGR of 16.69% during 2021-2028|
|Segment Covered||Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||BD, F. Hoffmann-La Roche Ltd, Propeller Health, BioCorp, Antares Pharma, Novartis AG, 3M, Sulzer Ltd, Gerresheimer AG, Sanofi, Johnson & Johnson Services, Inc., Bayer AG, GlaxoSmithKline plc, Novosanis, MEDMIX SYSTEMS AG, Merck & Co., Inc., Pfizer Inc., Insulet Corporation, OraSure Technologies, Inc., Enable Injections, West Pharmaceutical Services, Inc., SMC Ltd., ViVO Smart Medical Devices Ltd., and Cipla Inc.|
Key Segmentation of the Global Connected Drug Delivery Market 2018-2025
Connected Drug Delivery Devices Product Outlook (Revenue, USD Million, 2018 - 2025)
- Connected Sensors
- Inhaler Sensors
- Injection Sensors
- Integrated Connected Devices
- Integrated Inhalation Devices
- Integrated Injection Devices
Connected Drug Delivery Devices End-user Outlook (Revenue, USD Million, 2018 - 2025)
- Healthcare Providers
- Homecare Centers
Connected Drug Delivery Devices Technology Outlook (Revenue, USD Million, 2018 - 2025)
- Other Technologies (Cellular, Low Power Wide Area Network)
Connected Drug Delivery Devices Regional Outlook (Revenue, USD Million, 2018 - 2025)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- South Africa